Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;23(7):774-789.
doi: 10.1111/hiv.13262. Epub 2022 Feb 24.

Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe

Barbara Rossetti  1 , Massimiliano Fabbiani  1 , Domenico Di Carlo  2 , Francesca Incardona  3   4 , Ana Abecasis  5 , Perpetua Gomes  6   7 , Anna Maria Geretti  8   9 , Carole Seguin-Devaux  10 , Federico Garcia  11   12   13 , Rolf Kaiser  14 , Sara Modica  1 , Adrian Shallvari  4 , Anders Sönnerborg  15 , Maurizio Zazzi  16 ; EuResist Network, INTEGRATE study group
Collaborators, Affiliations
Free article

Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe

Barbara Rossetti et al. HIV Med. 2022 Aug.
Free article

Abstract

Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects.

Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated.

Results: Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5-3.8] in IN-NV, 18.4% (95% CI: 15.8-21.2) in IN-V, 4.2% (95% CI: 3.6-4.9) in IE-NV and 23.9% (95% CI: 20.9-26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1-13.0) in IN-NV, 19.6% (95% CI: 17.5-21.6) in IN-V, 10.8% (95% CI: 10.0-11.6) in IE-NV and 21.7% (95% CI: 19.7-23.5) in IE-V subjects.

Conclusions: Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.

Keywords: HIV; INSTI; dolutegravir; effectiveness; elvitegravir; integrase strand transfer inhibitors; raltegravir; treatment-experienced.

PubMed Disclaimer

References

REFERENCES

    1. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. doi:10.1056/NEJMoa1506816
    1. TEMPRANO ANRS Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in africa. N Engl J Med. 2015;373(9):808-822. doi:10.1056/NEJMoa1507198
    1. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on ART across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492-500. doi:10.1097/COH.0000000000000298
    1. EACS. EACS Guidelines Version 10.0. 2019. http://www.eacsociety.org/files/2019_guidelines-10.0-english.pdf. Accessed October 1, 2020.
    1. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV World Health Organization; 2018. https://www.who.int/hiv/pub/guidelines/ARV2018update/en/. Accessed October 1, 2020.

Publication types

MeSH terms